Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 92

Results For "disease"

2672 News Found

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
News | September 25, 2024

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022

She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all


WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines
Clinical Trials | September 23, 2024

WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results


Bavarian Nordic receives EMA approval of mpox vaccine for adolescents
Drug Approval | September 23, 2024

Bavarian Nordic receives EMA approval of mpox vaccine for adolescents

MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA


Fasenra recommended for approval in the EU by CHMP for treatment of EGPA
Drug Approval | September 23, 2024

Fasenra recommended for approval in the EU by CHMP for treatment of EGPA

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids


AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024
News | September 20, 2024

AstraZeneca Pharma India to launch Palivizumab (Synagis) in October 2024

Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease


Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
News | September 20, 2024

Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL

Stable profits, low leverage to keep credit profiles comfortable


Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
News | September 20, 2024

Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan

This license will enable Abbott to enhance access to this novel therapy to more patients across India


Lupin receives USFDA approval for Bumetanide Injection
Drug Approval | September 19, 2024

Lupin receives USFDA approval for Bumetanide Injection

Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.


Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
Drug Approval | September 19, 2024

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids


Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
News | September 18, 2024

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India